Chapter

PSA as a marker of progression and response in advanced prostate cancer

Yohann Loriot, Marine Gross-Goupil and Karim Fizazi

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI: http://dx.doi.org/10.1093/med/9780199561421.003.0002

Series: Oxford Oncology Library

PSA as a marker of progression and response in advanced prostate cancer

Show Summary Details

Preview

• Serum PSA is commonly used in prostate cancer patients to assess response to definitive local therapy and to detect relapse after definitive treatment in localized disease • A low PSA nadir is associated with longer survival after endocrine treatment of metastatic prostate cancer, though survival predictions from PSA parameters are not accurate • Though PSA is used to evaluate response to chemotherapy and in clinical trials assessing new drugs in prostate cancer, it is unclear whether decline in serum PSA is a surrogate for overall survival • Physicians should be aware of the postchemotherapy PSA surge syndrome during the first weeks following chemotherapy for CRPC, to preclude early discontinuation of chemotherapy in the erroneous assumption that progression has occurred.

Chapter.  2695 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.